MSF published a technical brief analysing access challenges concerning three Bundibugyo Ebola Virus therapeutic candidates - MBP134, remdesivir, and obeldesivir.
Our programmes in Malawi and Mali contribute to showing that it is possible to diagnose, prevent, and treat cancer in fragile and humanitarian settings. We’re speaking at the World Cancer Conference this week to share our experience:
